These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 38241354)

  • 1. Risk assessment in liver transplantation for hepatocellular carcinoma: long-term follow-up of a two-centre experience.
    Wehrle CJ; Raj R; Maspero M; Satish S; Eghtesad B; Pita A; Kim J; Khalil M; Calderon E; Orabi D; Zervos B; Modaresi Esfeh J; Whitsett Linganna M; Diago-Uso T; Fujiki M; Quintini C; Kwon CD; Miller C; Pinna A; Aucejo F; Hashimoto K; Schlegel A
    Int J Surg; 2024 May; 110(5):2818-2831. PubMed ID: 38241354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
    Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
    Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
    Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shadows Behind Using Simple Risk Models in Selection of Hepatocellular Carcinoma Patients for Liver Transplantation.
    Grąt M; Stypułkowski J; Morawski M; Wronka KM; Wasilewicz M; Lewandowski Z; Grąt K; Wójcik Z; Patkowski W; Zieniewicz K
    Ann Surg; 2020 Jun; 271(6):1124-1131. PubMed ID: 30601254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
    Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
    JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
    Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
    BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient and tumour biology predict survival beyond the Milan criteria in liver transplantation for hepatocellular carcinoma.
    Andreou A; Gül S; Pascher A; Schöning W; Al-Abadi H; Bahra M; Klein F; Denecke T; Strücker B; Puhl G; Pratschke J; Seehofer D
    HPB (Oxford); 2015 Feb; 17(2):168-75. PubMed ID: 25263399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living donor liver transplantation or resection for Child-Pugh A hepatocellular carcinoma patients with multiple nodules meeting the Milan criteria.
    Jiang L; Liao A; Wen T; Yan L; Li B; Yang J
    Transpl Int; 2014 Jun; 27(6):562-9. PubMed ID: 24606007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological differentiation predicts post-liver transplantation survival time.
    Li WX; Li Z; Gao PJ; Gao J; Zhu JY
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
    Otto G; Schuchmann M; Hoppe-Lotichius M; Heise M; Weinmann A; Hansen T; Pitton MP
    J Hepatol; 2013 Aug; 59(2):279-84. PubMed ID: 23587474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
    Cucchetti A; Serenari M; Sposito C; Di Sandro S; Mosconi C; Vicentin I; Garanzini E; Mazzaferro V; De Carlis L; Golfieri R; Spreafico C; Vanzulli A; Buscemi V; Ravaioli M; Ercolani G; Pinna AD; Cescon M
    J Hepatol; 2020 Aug; 73(2):342-348. PubMed ID: 32201284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.